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sAntagonism of miR-33 in Mice Promotes Reverse Cholesterol Trans-
port and Regression of Atherosclerosis
Rayner KJ, Sheedy FJ, Esau CC, et al. J Clin Invest 2011;121:2921-31.
Conclusion: Anti-miR33 oligonucleotide treatment promotes reverse
cholesterol transport and regression of atherosclerosis.
Summary: For every 1% increase in circulating HDL cholesterol
(HDL-C), there is a 2% decrease in overall risk for development of coronary
artery disease (Wilson PW. Am J Cardiol 1990;66:7A-10A). It has been
found in mouse models of atherosclerosis that over expression of apoA1,
which increases HDL levels, hinders plaque progression and promotes
plaque regression (Plump AS, et al. Proc Natl Acad Sci USA 1994;91:
9607-11 and Rong JX, et al. Circulation 2001;104:2447-52). Such evi-
dence has stimulated an interest in therapies to raise HDL levels. Despite the
fact HDL raising strategies may be effective therapy for atherosclerosis, the
underlying mechanisms that contribute to HDL regulation and its manip-
ulation for therapy remain poorly understood.
Recent advances in lipid metabolism reveal that miR-33, and intronic
microRNA within the SREBF 2 gene, suppresses expression of the ABC
cholesterol transporter and decreases circulatingHDL levels. This suggests a
possible strategy of antagonism of miR-33 to be atheroprotective. The
authors assessed the impact of miR-33 in mice deficient for the LDL
receptor (LDLR-/-mice) who had established atherosclerotic plaque. With 4
weeks of treatment of anti miR-33, there was increased circulating HDL
levels and enhanced reverse cholesterol transport to the plasma, liver, and
feces. Anti miR-33-treated mice showed reduction in plaque size and lipid
content. They also demonstrated increased markers of plaque stability and
decreased inflammatory gene expression. Anti miR-33 raised ABCA1 levels
in the liver. Anti miR-33 olgonucleotides directly targeted plaque macro-
phages and enhanced ABCA1 expression and cholesterol removal.
Comment: This study demonstrates that HDL generated by antago-
nism of miR-33 is functional and promotes removal of excess cholesterol
from atherosclerotic plaques into the reverse cholesterol transport pathway
thereby allowing for cholesterol excretion. Other effects of anti-miR33
included reduction in the lesion area, macrophage number, lipid content,
and inflammatory gene expression. The study demonstrates for the first time
that olgonucleotides can penetrate atherosclerotic plaque, reach lesion mac-
rophages, and enhance cholesterol removal. All of this could eventually
result in clinically relevant regression of atherosclerosis.
Decreased Kidney Function an Unrecognized and Often Untreated
Risk Factor for Secondary Cardiovascular Events After Carotid
Surgery
Van Lammeren GW, Moll FL, Blakestijn PJ, et al. Stroke 2011;42:307-12.
Conclusions: Patients with moderate kidney failure have an increased
risk of cardiovascular death and an increased risk of myocardial infarction 3
years after carotid endarterectomy (CEA) compared with patients with
normal or mild renal impairment.
Summary:The prevalence of chronic kidney disease (CKD) in the US
is currently estimated to be 9.6% of the population (Coresh J, et al. J Am Soc
Nephrol 2005;16:180-8) and increasing. Impaired kidney function in-
creases risk of death and hospitalization, and while CKD is irreversible, it is
treatable. Angiotensin-converting enzyme inhibitors (ACE inhibitors) and
angiotensin II antagonists can delay progression of CKD (Brenner BM, et al.
N Engl J Med 2001;345:861-9). This study sought to assess cardiovascular
mortality andmorbidity following carotid endarterectomy (CEA) in patients
with moderate kidney failure and to determine what proportion of patients
with moderate kidney failure receive optimal medical treatment or undergo
workup of their renal failure prior to CEA.
There were 1085 patients who underwent CEA between 2002 and
2009 who were included in the study. Baseline estimated glomerular filtra-
tion rate (eGFR) was assessed, and eGFR of 30-59 was defined as moderate
kidney failure. Patients with moderate kidney failure were compared with
those with normal or mildly reduced kidney function (eGFR60). Primary
endpoints were cardiovascular death (fatal myocardial infarction, fatal
stroke, and ruptured abdominal aortic aneurysm). Secondary endpoints
were cardiovascular morbidity. In this study population, 26.5% (n 288) of
the patients had moderate kidney failure. Median follow-up was 2.95 years
(0 to 3.0 years). The adjusted hazard ratio for cardiovascular death with
moderate kidney failure was 2.22 (1.27-3.89). The adjusted hazard ratio for
myocardial infarction with moderate kidney failure was 1.90 (1.04 to 3.47).
There was no increased rate of peripheral interventions or stroke in the
patients with moderate kidney failure. Of the patients with moderate kidney
g
Aailure, 38.3% (105/274) received ACE inhibitors. Only 34.4% had visited a
ephrologist and 75% had received statins.
Comment: The short-term risk of moderate kidney failure is largely
nrecognized by many surgeons. There are no widespread formal screening
rograms for moderate kidney failure, but all vascular surgery patients
ndergo basic metabolic testing and therefore, in essence, are screened for
nderlying kidney disease. Based on these data, vascular surgeons should
onsider referral to a nephrologist for any patient they identify with even
oderate renal insufficiency.
DL Promotes Rapid Atherosclerosis Regression in Mice and Alters
nflammatory Properties of Plaque Monocyte-Derived Cells
eig JE, Rong JX, Shamir R, et al. PNAS 2011;108:7166-71.
Conclusion: HDL cholesterol (HDL-C) is an in vivo regulator of
igratory and inflammatory properties of monocyte- derived cells in mouse
therosclerotic plaques.
Summary: There is an inverse relationship between HDL-C and
ardiovascular risk. HDL-C has been shown to be atheroprotective in mouse
odels of atherosclerosis (Rubin EM. Nature 1991;353:265-7). Infusion of
DL-C into human subjects has been shown to reduce plaque size (Nissen
E. JAMA 2003;290:2292-300). The authors, therefore, postulated
DL-C may be an effective therapy to induce regression of established
therosclerosis. They sought to examine the molecular effects of HDL -C on
therosclerotic plaque cells in vivo utilizing a mouse transplantation model
f atherosclerosis (Reis ED, et al. J Vas Surg 2001;34:541-7).
Plaque bearing aortic arches from apoplipoprotein E-deficient
ApoE-/- ) mice ( low HDL-C, high non-HDL-C) were transplanted into
ice with differing levels of HDL-C and non-HDL-C (C57BL6 mice
normal HDL-C, low non HDL-C]), apoA-/- mice (low HDL-C, low non
DL-C) or apoE -/-mice transgenic for human APOAI(hAI/apoE -/-;
ormal HDL-C , high non HDL-C). In persistently elevated non HDL-C
AL/apoE -/-recipients, CD68 cell count decreased in plaques by more
han 50% 1 week after transplantation. Little change in CD68 cell content
as observed in apoAL -/-recipient mice despite low lipid levels. Immigra-
ion and induction of chemokine receptor CCR7 was associated with
ecreased content of plaque CD68 cells. In CD68cells laser captured
rom plaques, normalization of HDL-C levels led to decreased expression of
nflammatory markers related to macrophages. No beneficial changes were
bserved in apoAI -/-recipients indicating a requirement for reverse choles-
erol transport for beneficial effects of HDL-C.
Comment: Data indicate that HDL-C in vivo is a regulator of migra-
ory and inflammatory properties of monocyte-derived cells found in mouse
therosclerotic plaques. These effects were independent of plasma non-
DL-C levels. This indicates HDL-C maybe an independent therapeutic
arget to promote atherosclerotic plaque regression through a mechanism of
odifying the population of monocyte-derived cells in atherosclerotic
laques.
eta-Analysis of Postoperative Mortality After Elective Repair of
bdominal Aortic Aneurysms Detected by Screening
indholt JS, Norman PE. Brit J Surg 2011;98:619-22.
Conclusion:Men whose abdominal aortic aneurysms (AAA) are iden-
ified through screening have improved early survival following operation
ompared to men whose AAAs are detected incidentally.
Summary: An incidentally detected AAA is an AAA found in the
valuation for another medical problem. AAAs detected with screening are
etected in patients without an active medical problem. Patients with
ncidentally detected AAAs may be at increased risk for AAA surgery because
f greater age, increased comorbidities, or more anatomically complex AAAs
han those whose AAAs are detected through a screening program. The
uthors thought to compare 30-day mortality of elective AAA surgery in
en whose aneurysms were detected incidentally vs those whose were
etected by screening. The authors analyzed reports from randomized trials
f AAA screening. Reports were identified through a systematic search of
EDLINE. Four relevant trials were identified and were also supplemented
ith data from the authors home institution.Meta-analysis was preformed as
xed odd ratios (OR) with 95% competence intervals. Heterogeneity be-
ween the studies was assessed using the 2 test. In the screening studies,
here were 25 deaths (2.9 %) following elective surgery in men invited for
creening (n  858) compared with 21 deaths in 383 men in the control
roup (5.5%; OR, 0.49; 0.27 to 0.88). There were 747 screened detected
AAs with 18 deaths (2.4%) in those operated on for screened detected
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November 20111536 AbstractsAAAs. There were 28 deaths (6.1%) following elective repair of 459 inciden-
tally detected AAAs (OR, 0.37; 0.24 to 0.68).
Comment: The risk of death in a male patient 65 years operated for
an incidentally detected aneurysm is approximately three times more than
one operated on for a screened detected AAA. The data do not permit a
“drill down” for why patients operated on for screened AAAs have lower
operative mortality than those operated on for incidentally detected AAAs.
Reasons could include lower ages and decreased comorbidities of screened
patients. Also, screened patients may have smaller aneurysms and/or less
complex anatomy permitting a higher proportion of endovascular repairs.
Overall, however, the author’s data provid another bit of evidence to
encourage screening in patients at risk at for AAA.
Proposed Chronic Cerebrospinal Venous Insufficiency Criteria DoNot
Predict Multiple Sclerosis Risk or Severity
Centonze D, Floris R, Stefanini M, et al. Ann Neurol 2011;70:51-8.
Conclusion: Chronic cerebrospinal venous insufficiency (CCSVI) has
no role in either multiple sclerosis (MS) risk or MS severity.
Summary: Anatomic abnormalities of major neck and chest veins are
proposed to impair central nervous system venous drainage. Zamboni has
proposed that CCSVI has a strong association withmultiple sclerosis (J Neu-
rol Neurosurg Psychiatry 2009;80:382-99). His results indicate MS is
caused by CCSVI and that CCSVI plays a substantial role inMS progression.
Endovascular interventions directed to correct abnormalities of venous
drainage reportedly characteristic of CCSVI could potentially improve the
clinical course of MS (Zamboni P, et al. J Vasc Surg 2009;50:1348-58).
However, some question the very existence of CCSVI (Doepp F et al. Ann
Neurol 2010;68:173-83).
It has been suggested that studies failing to demonstrate a significant
association between CCSVI and MS use alternative approaches to define
CCSVI than those utilized by Zamboni et al. The authors, therefore, utilized
an experimental protocol they feel is identical to that developed by Zamboni
and coworkers. This protocol was applied to an independent population of
MS patients and healthy controls by operators specifically trained by Dr
Zamboni in CCSVI identification.
The Zamboni method for CCSVI identification was studied in 84 MS
patients and 56 healthy subjects. There were no significant differences (P 
.12) in CCSVI frequency between MS and control subjects. No differences
were found between CCSVI-positive and CCSVI-negative patients with
respect to MS duration, time between MS onset and first relapse, relapsing
progressive MS, and risk of secondary progression. There were no statistical
differences found between CCSVI-positive and CCSVI-negative MS sub-
jects by analyzingmeasures of disability such as the mean expanded disability
status scale (P .07) mean progressive index (P .1) and meanMS severity
score (P  .1). The percentage of subjects who reached expanded disability
status scale 4.0 and 6.0 was not different among CCSVI-negative and
CCSVI-positive patients. There was no difference found between severity of
disability and number of positive CCSVI criteria.
Comment: This paper disputes the Zamboni theory of CCSVI as the
etiology of MS. By using ultrasound operators specifically trained by Zam-
boni, the authors sought to dissuade the arguments utilized to criticize
previous negative studies as being secondary to inappropriate operator
training or skills. The results here, put simply, do not support a role of
venous abnormalities in MS. It is still premature and, in many respects,
perhaps irresponsible to offer endovascular procedures to correct CCSVI in
the MS patient population.
Symptomatic Internal Carotid Artery Occlusion: A Long-Term Fol-
low-Up Study
Persoon S, Luitse MJA, de Borst G, et al. J Neurol Neurosurg Psychiatry
2011;82:521-6.
Conclusion: In patients with minor stroke or transient ischemic attack
(TIA) and internal carotid artery (ICA) occlusion, recurrent ischemic stroke
is infrequent compared to other vascular events and is dependent upon
clinical factors and the presence of leptomeningeal collaterals.
Summary: In the short- to medium-term, patients with TIA or stroke
associated with occlusion of the ICA appear to have a risk of recurrent stroke
of approximately 5% per year (Klijn CJM, et al. Cebrovas Dis 2001;12:228-
34). The authors previously reported short-term data on prognosis of
patients with symptomatic ICA occlusion with respect to hemodynamic
compromise of the ICA distribution ( Klijn CJM, et al. Neurology 2000;55:
1806-12). The current study represents long-term data of this original
cohort with respect to hemodynamic characteristics of the brain and risk of
ischemic stroke.
There were 117 consecutive patients with TIAs or moderately disabling
cerebral or retinal ischemia associated with ICA occlusion entered into the
study between September 1995 and July 1998 and followed until June
2008. The risk of recurrent ischemic stroke and other vascular events was
analyzed. These variables were analyzed with respect to potentially prognos-
c
sic factors, including collateral pathways and transcranial Doppler CO2
eactivity.
The mean age of the patients was 61 9 years; 80% were male. Median
ollow-up was 10.2 years. Twenty-two patients underwent carotid endarter-
ctomy for contralateral ICA stenosis and 16 had extracranial/intracranaial
ypass surgery. Twenty-three patients had recurrent ischemic stroke com-
uting to an annual rate of 2.4% (95% CI, 1.5 to 3.6). Risk factors for
ecurrent ischemic stroke were cerebral rather than retinal symptoms (HR,
.0; 1.0260), recurrent symptoms after ICA occlusion (HR, 4.4; 1.6 to 12),
imb-shaking TIAs at presentation (HR, 7.5; 2.6 to 22), age (HR, 1.07;
.02 to 1.13), history of stroke (HR, 2.8;1.2 to 6.7), and leptomeningeal
ollaterals (HR, 5.2; 1.5 to 17). CO2 reactivity was not a risk factor for
ecurrent ischemic stroke (HR, 1.01; 0.99 to 1.02). Vascular events in
ollow-up were frequent and occurred in 57 patients for annual rate of 6.4%
95% CI, 4.9 to 8.2).
Comment: The medical arm of the EC/IC bypass trial (EC/IC bypass
tudy group. NEJM 1985;313:1191-200) is the largest cohort of medically
reated patients with symptomatic ICA occlusion. Follow-up in that study
as 4.5 years and the mean annual risk of ischemic stroke was 6.3%. The
uthors lower observed risk of recurrent ischemic stroke may be related to
etter medical management than in the 1980s. Also, inclusion of a larger
ercentage of patients with retinal symptoms may have lowered overall risk.
he high rate of other vascular events in patients with ICA occlusion argues
or aggressive management of atherosclerotic risk factors in these pateints.
hile leptomeningeal collaterals appear predictive of recurrent ischemic
troke, it is not suggested that with patients ICA occlusion undergo routine
ngiography. Whether or not EC/IC bypass surgery will prevent stroke in
atients with hemodynamic compromise is currently under investigation
GRUBB, RL Jr, et al Neurosurg Focus 2003;14:e9).
rends in Patient Reported Outcomes of Conservative and Surgical
reatment of Primary Chronic Venous Disease Contradict Current
ractices
urie F, Kistner RL. Ann Surg 2011;254:363-7.
Conclusion: For patients with primary chronic venous disease, surgical
reatment provides better symptom relief compared to conservative therapy.
elief of symptoms after conservative therapy predicts better outcomes
ollowing surgical treatment.
Summary: Many insurance policies will only approve treatment for
aricose veins when medically necessary, with medical necessity defined as
ailure to obtain symptom relief with conservative management. Conserva-
ive management is generally the use of a graduated compression stockings
or 1 to 6 months. There is, however, no evidence that conservative therapy
bviates further improvement with surgical treatment. The potential of
urther improvement in symptoms with surgical therapy for patients who
ave improved with conservative therapy is not known. In assessing the
ffects of conservative therapy of chronic venous disease, few studies have
tilized patient-reported outcomes. Patient-centered medicine, in essence,
equires examination of practice guidelines and polices from the patient
erspective of treatment outcomes.
The purpose of this study was to analyze patient reported quality of life
nd symptoms in a cohort of chronic venous disease patients managedwithin
he framework of existing policies. This was a prospective cohort study of
50 patients with C2-C4 primary chronic venous disease. Initial manage-
ent included conservative measures, following which patients were given a
hoice of continuing conservative therapy, or moving on to surgical therapy.
ne and 12 month follow-up visits were scheduled after surgical therapy.
uality of life (QOL) scores and symptom score (SS) were analyzed sepa-
ately. Conservative treatment provided improvement of symptom scores in
5 (57% of patients) and in QOL scores in 111 (74%) patients. Even though
he majority of patients improved, 121 elected surgical treatment after a
eriod of conservative therapy. One month after surgical treatment, 80% of
atients (n 97) had further significant improvement of symptoms and 114
94%) had further improvement in QOL scores compared to their after
onservative therapy period. Improvements in the QOL scores were due
ainly to improvements in symptoms. If patients improved after conserva-
ive therapy, they were more than 15 times more likely to have symptom
elief at 1 month following surgical therapy (relative risk  15.6; 95%CI,
.3-56.5) and at 1 year were 21 timesmore likely to have improved symptom
elief following surgery (relative risk  21.3; 95%CI, 4.7-96.9).
Comment: Conservative therapy for patients with primary chronic
enous disease improves symptoms and quality of life. The provocative piece
f this paper is to suggest improvement with conservative therapy should not
e used to withhold surgical therapy, but actually serves as a marker for
atients who will improve further with surgical therapy. The findings con-
radict the present practice of insurance companies interpreting success of
onservativemeasures as a contraindication to surgical treatment. In essence,
uccess of conservative therapy arguably is an indication for surgical therapy.
